Polaryx Therapeutics, Inc.
NCM: PLYXLive Quote
About Polaryx Therapeutics, Inc.
Healthcare
Biotechnology
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
📊 Fundamental Analysis
Polaryx Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -193.7%, which indicates that capital utilization is currently under pressure.
At a current price of $5.68, PLYX currently trades near the bottom of its 52-week range (7%), indicating potential value or weakness (Range: $2.20 - $48.91).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
Key Financials
Market Cap
$132.56M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
--
52W High
$48.91
52W Low
$2.20
Avg Volume
2.31M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App